KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition. Several strategies are under investigation for inhibiting oncogenic KRA...

Descripció completa

Dades bibliogràfiques

Autors principals:	Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, Avrosina Kamel, Ariel Liberchuk, Andrew L. Wolfe
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2024-04-01
Col·lecció:	Current Oncology
Matèries:	KRAS cancer immunotherapy targeted therapy resistance oncogene
Accés en línia:	https://www.mdpi.com/1718-7729/31/4/150
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!